Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria

被引:13
|
作者
Gæde, P [1 ]
Vedel, P [1 ]
Parving, HH [1 ]
Pedersen, O [1 ]
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
cardiovascular disease; endothelial dysfunction; microalbuminuria; microvascular complications; type 2 diabetes mellitus; von Willebrand factor;
D O I
10.1093/ndt/16.10.2028
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The purpose of this study was to examine the concept suggesting that microalbuminuria in combination with high levels of plasma von Willebrand factor is a stronger predictor for cardiovascular disease and microvascular complications than microalbuminuria alone in type 2 diabetic patients. Methods. One hundred and sixty patients with type 2 diabetes mellitus and persistent microalbuminuria were followed for an average of 3.8 (SD 0.3) years. 70%, of the patients were treated with angiotensin converting enzyme (ACE)-inhibitors. Patients in this subanalysis were divided into two groups according to baseline plasma von Willebrand factor levels below or above the median. The main outcome was cardiovascular disease (cardiovascular mortality. non-fatal stroke. non-fatal myocardial infarction. coronary artery bypass graft and revascularization or amputation of legs), progression to diabetic nephropathy or progression in diabetic retinopathy. Results. At baseline the two groups were comparable for HbA(jc) fasting levels of s-total-cholesterol, s-HDL-cholesterol and s-triglycerides. systolic and diastolic blood pressure, gender, known diabetes duration, smoking habits. previous cardiovascular disease and antihypertensive therapy as well as retinopathy. Odds ratio for cardiovascular disease was 1.11 (95% CI 0.45-2.73, P = 0.82) (multiple logistic regression), odds ratio for progression to nephropathy was 1.08 (0.41 2.85, P = 0.87) and odds ratio for progression in retinopathy was 0.96 (0.46-2.00, P = 0.92), all with plasma von Willebrand factor levels above the median. Conclusions. Our results do not support the suggestion that the combination of high plasma levels of von Willebrand factor and microalbuminuria is a stronger predictor for cardiovascular disease. progression to diabetic nephropathy or progression in diabetic retinopathy than microalbuminuria alone in patients with type 2 diabetes and persistent microalbuminuria.
引用
收藏
页码:2028 / 2033
页数:6
相关论文
共 50 条
  • [31] Impact of annexin A2 SNP on von Willebrand factor levels in patients with moderate and severe von Willebrand disease
    Van Heerde, W.
    van Puffelen, J.
    Kloots, I
    Boender, J.
    Sanders, Y.
    Cnossen, M.
    Laros-van Gorkom, B.
    Fijnvandraat, K.
    Schoormans, S.
    van der Bom, J.
    Meijer, K.
    Mauser-Bunschoten, E.
    Eikenboom, J.
    Kiemeney, L.
    Leebeek, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 172 - 173
  • [32] Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease
    Hirano, T
    Ookubo, K
    Kashiwazaki, K
    Tajima, H
    Yoshino, G
    Adachi, M
    CLINICA CHIMICA ACTA, 2000, 299 (1-2) : 65 - 75
  • [33] Elevated triglycerid levels are a significant risk factor for early development of diabetic nephropathy in type 2 diabetic patients
    Mauler, H
    Abrahamian, H
    Kaida, A
    Rabensteiner, D
    Irsigler, K
    Prager, R
    DIABETOLOGIA, 2001, 44 : A267 - A267
  • [34] Low platelet α2β1 levels in patients with type 1 von Willebrand disease represent an increased risk factor for bleeding.
    Federici, AB
    Mannucci, PM
    Canciani, MT
    Cozzi, G
    Di Paola, J
    Kunicki, TJ
    Nugent, D
    THROMBOSIS RESEARCH, 1998, 91 (03) : S6 - S7
  • [35] Monitoring for von Willebrand factor inhibitors in patients with von Willebrand disease Type 3.
    Miller, CH
    DiMichele, DM
    Hilgartner, MW
    BLOOD, 1997, 90 (10) : 135 - 135
  • [36] Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease
    Casonato, Alessandra
    Gallinaro, Lisa
    Pontara, Elena
    Bernardo, Letizia
    Sartorello, Francesca
    Daidone, Viviana
    Pagnan, Antonio
    THROMBOSIS RESEARCH, 2007, 120 (03) : 451 - 453
  • [37] Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy
    Cambronero, Francisco
    Antonio Vilchez, Juan
    Garcia-Honrubia, Antonio
    Ruiz-Espejo, Francisco
    Moreno, Victoria
    Hernandez-Romero, Diana
    Bonacasa, Barbara
    Gonzalez-Conejero, Rocio
    de la Morena, Gonzalo
    Martinez, Pedro
    Climent, Vicente
    Valdes, Mariano
    Marin, Francisco
    THROMBOSIS RESEARCH, 2010, 126 (01) : E46 - E50
  • [38] Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease
    Sztukowska, M.
    Gallinaro, L.
    Cattini, M. G.
    Pontara, E.
    Sartorello, F.
    Daidone, V.
    Padrini, R.
    Pagnan, A.
    Casonato, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (01) : 107 - 114
  • [39] Increased LDL/HDL ratio but not elevated levels of von Willebrand factor antigen as characteristic feature in patients with essential hypertension and moderate microalbuminuria
    Biesenbach, G
    Janko, O
    Zazgornik, J
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1998, 27 (10) : 456 - 460
  • [40] Monitoring Of IGF-1 Levels In Type 2 Diabetic Patients With Macro And Microvascular Complications
    Wasim, H.
    Abdelmonem, M.
    Samir, S.
    Salah, A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S127 - S128